Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders.

[1]  G. Marsicano,et al.  Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse , 2016, Neuroscience.

[2]  R. Franco,et al.  Neuroprotective Effect of JZL184 in MPP+-Treated SH-SY5Y Cells Through CB2 Receptors , 2016, Molecular Neurobiology.

[3]  S. Petrosino,et al.  The anti‐inflammatory mediator palmitoylethanolamide enhances the levels of 2‐arachidonoyl‐glycerol and potentiates its actions at TRPV1 cation channels , 2016, British journal of pharmacology.

[4]  M. Triggiani,et al.  Human lung‐resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors , 2016, Journal of leukocyte biology.

[5]  S. Cuzzocrea,et al.  A novel protective formulation of Palmitoylethanolamide in experimental model of contrast agent induced nephropathy. , 2016, Toxicology letters.

[6]  Yumin Zhang,et al.  Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis , 2015, Neuropharmacology.

[7]  M. Shabani,et al.  Palmitoylethanolamide attenuates PTZ-induced seizures through CB1 and CB2 receptors , 2015, Epilepsy Research.

[8]  U. Taschler,et al.  Genetic deletion of monoacylglycerol lipase leads to impaired cannabinoid receptor CB1R signaling and anxiety‐like behavior , 2015, Journal of neurochemistry.

[9]  O. Albayram,et al.  Enhanced microglial activity in FAAH(-/-) animals. , 2015, Life sciences.

[10]  W. Notcutt.  Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis , 2015, Neurotherapeutics.

[11]  A. Usiello,et al.  Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice , 2015, Molecular Brain.

[12]  Yi Dai,et al.  Evodiamine suppresses capsaicin-induced thermal hyperalgesia through activation and subsequent desensitization of the transient receptor potential V1 channels , 2015, Journal of Natural Medicines.

[13]  M. Loriot,et al.  Expression in yeast, new substrates, and construction of a first 3D model of human orphan cytochrome P450 2U1: Interpretation of substrate hydroxylation regioselectivity from docking studies. , 2015, Biochimica et biophysica acta.

[14]  C. Guaza,et al.  A Sativex®‐like combination of phytocannabinoids as a disease‐modifying therapy in a viral model of multiple sclerosis , 2015, British journal of pharmacology.

[15]  S. Cuzzocrea,et al.  N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution , 2015, Molecular Neurobiology.

[16]  T. England,et al.  Endocannabinoids modulate human blood–brain barrier permeability in vitro , 2015, British journal of pharmacology.

[17]  M. Faizi,et al.  Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice , 2015, Neuroscience.

[18]  J. Jankovic,et al.  The therapeutic potential of cannabinoids for movement disorders , 2015, Movement disorders : official journal of the Movement Disorder Society.

[19]  J. Ioannidis,et al.  Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses , 2015, The Lancet Neurology.

[20]  B. Lutz,et al.  The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway , 2015, Cell Death and Differentiation.

[21]  A. Lo,et al.  Treatment of progressive multiple sclerosis: what works, what does not, and what is needed , 2015, The Lancet Neurology.

[22]  L. Facci,et al.  Neuroinflammation, microglia and mast cells in the pathophysiology of neurocognitive disorders: a review. , 2015, CNS & neurological disorders drug targets.

[23]  A. Pérez-Samartín,et al.  Blockade of monoacylglycerol lipase inhibits oligodendrocyte excitotoxicity and prevents demyelination in vivo , 2015, Glia.

[24]  R. Capasso,et al.  Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti‐inflammatory agent , 2015, British journal of pharmacology.

[25]  A. Kambalyal,et al.  Endocannabinoids Anandamide and 2-Arachidonoylglycerol Are Substrates for Human CYP2J2 Epoxygenase , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[26]  Wei Yang,et al.  Interferon-γ safeguards blood-brain barrier during experimental autoimmune encephalomyelitis. , 2014, The American journal of pathology.

[27]  L. Breydo,et al.  Mechanistic and Structural Analysis of Drosophila melanogaster Arylalkylamine N-Acetyltransferases , 2014, Biochemistry.

[28]  Zhenguo Liu,et al.  The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats , 2014, Drug design, development and therapy.

[29]  R. Franco,et al.  The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model , 2014, Neurobiology of Aging.

[30]  J. Lanciego,et al.  CB1 and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum , 2014, Experimental Neurology.

[31]  S. Cuzzocrea,et al.  Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer's disease models: the control of neuroinflammation. , 2014, CNS & neurological disorders drug targets.

[32]  F. Drago,et al.  The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis. , 2014, Pharmacological research.

[33]  P. Campolongo,et al.  Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease , 2014, Cell Death and Disease.

[34]  D. Križaj,et al.  TRPV1 and Endocannabinoids: Emerging Molecular Signals that Modulate Mammalian Vision , 2014, Cells.

[35]  C. Russo,et al.  Functional and biochemical interaction between PPARα receptors and TRPV1 channels: Potential role in PPARα agonists-mediated analgesia. , 2014, Pharmacological research.

[36]  D. McHugh,et al.  Novel endogenous N-acyl amides activate TRPV1-4 receptors, BV-2 microglia, and are regulated in brain in an acute model of inflammation , 2014, Front. Cell. Neurosci..

[37]  R. Meli,et al.  Palmitoylethanolamide in CNS health and disease. , 2014, Pharmacological research.

[38]  F. Fanelli,et al.  Neuroprotective properties of peroxisome proliferator-activated receptor alpha (PPARα) and its lipid ligands. , 2014, Current medicinal chemistry.

[39]  Benjamin J. Whalley,et al.  Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. , 2014, ACS chemical neuroscience.

[40]  T. Bisogno,et al.  Endocannabinoid signaling and its regulation by nutrients , 2014, Biofactors.

[41]  M. Mor,et al.  3‐Aminoazetidin‐2‐one Derivatives as N‐Acylethanolamine Acid Amidase (NAAA) Inhibitors Suitable for Systemic Administration , 2014, ChemMedChem.

[42]  T. Harkany,et al.  The endocannabinoid 2-AG controls skeletal muscle cell differentiation via CB1 receptor-dependent inhibition of Kv7 channels , 2014, Proceedings of the National Academy of Sciences.

[43]  J. Lanciego,et al.  Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease. , 2014, Journal of neuropathology and experimental neurology.

[44]  N. Stella,et al.  Modulation of Pilocarpine-Induced Seizures by Cannabinoid Receptor 1 , 2014, PloS one.

[45]  A. Roohbakhsh,et al.  Involvement of central TRPV1 receptors in pentylenetetrazole and amygdala-induced kindling in male rats , 2014, Neurological Sciences.

[46]  F Peter Guengerich,et al.  Oxidation of Endogenous N-Arachidonoylserotonin by Human Cytochrome P450 2U1* , 2014, The Journal of Biological Chemistry.

[47]  D. Merkler,et al.  Identification of an arylalkylamine N‐acyltransferase from Drosophila melanogaster that catalyzes the formation of long‐chain N‐acylserotonins , 2014, FEBS letters.

[48]  Jie Ren,et al.  Atheroprotective Effect of Oleoylethanolamide (OEA) Targeting Oxidized LDL , 2014, PloS one.

[49]  S. Petrosino,et al.  Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis , 2014, BMC Veterinary Research.

[50]  S. Frank.  Treatment of Huntington’s Disease , 2013, Neurotherapeutics.

[51]  Yumin Zhang,et al.  Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis , 2013, Neuroscience.

[52]  A. Eschalier,et al.  Monoacylglycerols Activate TRPV1 – A Link between Phospholipase C and TRPV1 , 2013, PloS one.

[53]  G. Martinotti,et al.  The Endocannabinoid System: A Putative Role in Neurodegenerative Diseases , 2013, International journal of high risk behaviors & addiction.

[54]  Luis E. Gonzalez-Reyes,et al.  TRPV1 antagonist capsazepine suppresses 4-AP-induced epileptiform activity in vitro and electrographic seizures in vivo , 2013, Experimental Neurology.

[55]  L. Mestre,et al.  Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors , 2013, Neurobiology of Disease.

[56]  R. Pertwee.  Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications , 2013, Proceedings of the Nutrition Society.

[57]  D. Julius.  TRP channels and pain. , 2013, Annual review of cell and developmental biology.

[58]  Patrice D Cani,et al.  Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6 , 2013, Proceedings of the National Academy of Sciences.

[59]  T. Bisogno,et al.  The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG , 2013, Cell Death and Disease.

[60]  A. Szallasi,et al.  Targeting TRP channels for pain relief. , 2013, European journal of pharmacology.

[61]  M. Prentki,et al.  Metabolic signaling in fuel-induced insulin secretion. , 2013, Cell metabolism.

[62]  R. Capasso,et al.  Analysis of the "endocannabinoidome" in peripheral tissues of obese Zucker rats. , 2013, Prostaglandins, leukotrienes, and essential fatty acids.

[63]  R. Mechoulam,et al.  N-arachidonoyl-L-serine (AraS) Possesses Proneurogenic Properties in Vitro and in Vivo after Traumatic Brain Injury , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[64]  R. Capasso,et al.  Anandamide-derived Prostamide F2α Negatively Regulates Adipogenesis , 2013, The Journal of Biological Chemistry.

[65]  V. Marzo,et al.  Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy , 2013, Neuropharmacology.

[66]  B. Roozendaal,et al.  Plasma Concentrations of Endocannabinoids and Related Primary Fatty Acid Amides in Patients with Post-Traumatic Stress Disorder , 2013, PloS one.

[67]  D. C. Medeiros,et al.  Effects of cannabinoids and endocannabinoid hydrolysis inhibition on pentylenetetrazole-induced seizure and electroencephalographic activity in rats , 2013, Epilepsy Research.

[68]  A. Finazzi Agro',et al.  Epigenetic mechanisms and endocannabinoid signalling , 2013, The FEBS journal.

[69]  T. Uyama,et al.  Metabolism of endocannabinoids and related N‐acylethanolamines: Canonical and alternative pathways , 2013, The FEBS journal.

[70]  J. Long,et al.  Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors , 2013, Multiple sclerosis.

[71]  K. Mackie,et al.  GPR55, a G-Protein Coupled Receptor for Lysophosphatidylinositol, Plays a Role in Motor Coordination , 2013, PloS one.

[72]  E. Ağar,,et al.  The Role of CB1‐Receptors in the Proconvulsant Effect of Leptin on Penicillin‐Induced Epileptiform Activity in Rats , 2013, CNS neuroscience & therapeutics.

[73]  E. Patsouris,et al.  The neuroprotective role of endocannabinoids against chemical‐induced injury and other adverse effects , 2013, Journal of applied toxicology : JAT.

[74]  B. Cravatt,et al.  The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. , 2013, Life sciences.

[75]  C. Russo,et al.  Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide , 2013, British journal of pharmacology.

[76]  S. Young,et al.  Biochemistry and pathophysiology of intravascular and intracellular lipolysis. , 2013, Genes & development.

[77]  R. Bertorelli,et al.  Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models , 2013, PAIN®.

[78]  J. Martínez-Orgado,et al.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? , 2013, British journal of clinical pharmacology.

[79]  S. Cuzzocrea,et al.  Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. , 2013, Mini reviews in medicinal chemistry.

[80]  S. Cuzzocrea,et al.  Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries. , 2013, CNS & neurological disorders drug targets.

[81]  D. Albrecht,et al.  Effects of single swim stress on changes in TRPV1-mediated plasticity in the amygdala , 2013, Behavioural Brain Research.

[82]  L. Petrocellis,et al.  Why do cannabinoid receptors have more than one endogenous ligand? , 2012, Philosophical Transactions of the Royal Society B: Biological Sciences.

[83]  M. Waldhoer,et al.  The Cannabinoid Receptor CB1 Modulates the Signaling Properties of the Lysophosphatidylinositol Receptor GPR55* , 2012, The Journal of Biological Chemistry.

[84]  S. Cuzzocrea,et al.  Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats , 2012, Brain Research.

[85]  Stephen P. H. Alexander,et al.  Lack of effect of chronic pre‐treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system , 2012, British journal of pharmacology.

[86]  F. Moradi,et al.  WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway , 2012, Neuropharmacology.

[87]  C. Guaza,et al.  A CB1/CB2 receptor agonist, WIN 55,212-2, exerts its therapeutic effect in a viral autoimmune model of multiple sclerosis by restoring self-tolerance to myelin , 2012, Neuropharmacology.

[88]  A. Lichtman,et al.  Production and Actions of the Anandamide Metabolite Prostamide E2 in the Renal Medulla , 2012, Journal of Pharmacology and Experimental Therapeutics.

[89]  Jin Fu,et al.  Design and Synthesis of Potent N-Acylethanolamine-hydrolyzing Acid Amidase (NAAA) Inhibitor as Anti-Inflammatory Compounds , 2012, PloS one.

[90]  E. Mazzon,et al.  Neuroprotective Activities of Palmitoylethanolamide in an Animal Model of Parkinson's Disease , 2012, PloS one.

[91]  Xuemei Zhang,et al.  Orally administered oleoylethanolamide protects mice from focal cerebral ischemic injury by activating peroxisome proliferator-activated receptor α , 2012, Neuropharmacology.

[92]  C. Cotman,et al.  An amyloid β42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease , 2012, Neurobiology of Aging.

[93]  Patrice D Cani.  Crosstalk between the gut microbiota and the endocannabinoid system: impact on the gut barrier function and the adipose tissue. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[94]  V. Di Marzo,et al.  Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis. , 2012, American journal of veterinary research.

[95]  S. Umathe,et al.  Involvement of transient receptor potential vanilloid type 1 channels in the pro-convulsant effect of anandamide in pentylenetetrazole-induced seizures , 2012, Epilepsy Research.

[96]  J. Ramos,et al.  Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects , 2012, Neuropharmacology.

[97]  B. Cravatt,et al.  β−Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR‐α, PPAR‐γ and TRPV1, but not CB1 or CB2 receptors , 2012, British journal of pharmacology.

[98]  R. Capasso,et al.  Inhibitory effect of cannabichromene, a major non‐psychotropic cannabinoid extracted from Cannabis sativa, on inflammation‐induced hypermotility in mice , 2012, British journal of pharmacology.

[99]  M. Jaber,et al.  Loss of Environmental Enrichment Increases Vulnerability to Cocaine Addiction , 2012, Neuropsychopharmacology.

[100]  L. Parsons,et al.  Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates. , 2012, Chemistry & biology.

[101]  R. Pertwee,et al.  Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors. , 2012, ACS chemical neuroscience.

[102]  A. Duranti,et al.  N-(2-oxo-3-oxetanyl)carbamic acid esters as N-acylethanolamine acid amidase inhibitors: synthesis and structure-activity and structure-property relationships. , 2012, Journal of medicinal chemistry.

[103]  B. Alger.  Endocannabinoids at the synapse a decade after the dies mirabilis (29 March 2001): what we still do not know , 2012, The Journal of physiology.

[104]  M. Janahmadi,et al.  CB1 Cannabinoid Receptor Activation Rescues Amyloid β-Induced Alterations in Behaviour and Intrinsic Electrophysiological Properties of Rat Hippocampal CA1 Pyramidal Neurones , 2012, Cellular Physiology and Biochemistry.

[105]  S. Popoff,et al.  The Endocannabinoids Anandamide and Virodhamine Modulate the Activity of the Candidate Cannabinoid Receptor GPR55 , 2012, Journal of Neuroimmune Pharmacology.

[106]  A. Lichtman,et al.  Discovery of Prostamide F2α and Its Role in Inflammatory Pain and Dorsal Horn Nociceptive Neuron Hyperexcitability , 2012, PloS one.

[107]  V. Di Marzo,et al.  Effects of intra-ventrolateral periaqueductal grey palmitoylethanolamide on thermoceptive threshold and rostral ventromedial medulla cell activity. , 2012, European journal of pharmacology.

[108]  J. Manzanares,et al.  Overexpression of CB2 cannabinoid receptors results in neuroprotection against behavioral and neurochemical alterations induced by intracaudate administration of 6-hydroxydopamine , 2012, Neurobiology of Aging.

[109]  D. Centonze,et al.  TRPV1 Channels Regulate Cortical Excitability in Humans , 2012, The Journal of Neuroscience.

[110]  M. Janahmadi,et al.  Protective effect of cannabinoid CB1 receptor activation against altered intrinsic repetitive firing properties induced by Aβ neurotoxicity , 2012, Neuroscience Letters.

[111]  J. Moreno-Navarrete,et al.  The l-α-Lysophosphatidylinositol/GPR55 System and Its Potential Role in Human Obesity , 2012, Diabetes.

[112]  G. Wenk,et al.  Can the benefits of cannabinoid receptor stimulation on neuroinflammation, neurogenesis and memory during normal aging be useful in AD prevention? , 2012, Journal of Neuroinflammation.

[113]  V. Marzo,et al.  Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide , 2011, Journal of cellular and molecular medicine.

[114]  A. Ross,et al.  Resolution of inflammation by N‐arachidonoylglycine , 2011, Journal of cellular biochemistry.

[115]  K. Verhoeckx,et al.  Presence, formation and putative biological activities of N-acyl serotonins, a novel class of fatty-acid derived mediators, in the intestinal tract. , 2011, Biochimica et biophysica acta.

[116]  G. Milligan,et al.  Heteromultimerization of Cannabinoid CB1 Receptor and Orexin OX1 Receptor Generates a Unique Complex in Which Both Protomers Are Regulated by Orexin A* , 2011, The Journal of Biological Chemistry.

[117]  B. Hyman,et al.  Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.

[118]  Z. Vogel,et al.  Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis‐like disease in C57BL/6 mice , 2011, British journal of pharmacology.

[119]  R. Mechoulam,et al.  N-Arachidonoyl-l-Serine is Neuroprotective after Traumatic Brain Injury by Reducing Apoptosis , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[120]  M. García-Arencibia,et al.  Symptom‐relieving and neuroprotective effects of the phytocannabinoid Δ9‐THCV in animal models of Parkinson's disease , 2011, British journal of pharmacology.

[121]  R. Talwar,et al.  Cannabinoid 1 (CB1) receptor--pharmacology, role in pain and recent developments in emerging CB1 agonists. , 2011, CNS & neurological disorders drug targets.

[122]  J. Holst,et al.  2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. , 2011, The Journal of clinical endocrinology and metabolism.

[123]  Benjamin F. Cravatt,et al.  Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain , 2011, Journal of Pharmacology and Experimental Therapeutics.

[124]  Z. Xi,et al.  Brain Cannabinoid CB2 Receptors Modulate Cocaine’s Actions in Mice , 2011, Nature Neuroscience.

[125]  A. M. Martín-Moreno,et al.  Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer's Disease , 2011, Molecular Pharmacology.

[126]  N. Naderi,et al.  Modulation of Anticonvulsant Effects of Cannabinoid Compounds by GABA-A Receptor Agonist in Acute Pentylenetetrazole Model of Seizure in Rat , 2011, Neurochemical Research.

[127]  P. Koulen,et al.  Lauroylethanolamide and linoleoylethanolamide improve functional outcome in a rodent model for stroke , 2011, Neuroscience Letters.

[128]  Masahiko Watanabe,et al.  Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. , 2011, Brain : a journal of neurology.

[129]  R. Zechner,et al.  Monoglyceride Lipase Deficiency in Mice Impairs Lipolysis and Attenuates Diet-induced Insulin Resistance* , 2011, The Journal of Biological Chemistry.

[130]  B. Bahr,et al.  A New Generation Fatty Acid Amide Hydrolase Inhibitor Protects Against Kainate-Induced Excitotoxicity , 2011, Journal of Molecular Neuroscience.

[131]  S. Hansen,et al.  Dietary fat decreases intestinal levels of the anorectic lipids through a fat sensor , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[132]  R. Piñeiro,et al.  The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation , 2011, Oncogene.

[133]  G. Hu,et al.  The putative cannabinoid receptor GPR55 promotes cancer cell proliferation , 2011, Oncogene.

[134]  M. Klugmann,et al.  AAV Vector-Mediated Overexpression of CB1 Cannabinoid Receptor in Pyramidal Neurons of the Hippocampus Protects against Seizure-Induced Excitoxicity , 2010, PloS one.

[135]  T. Bisogno,et al.  Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. , 2010, CNS & neurological disorders drug targets.

[136]  A. Araque,et al.  Endocannabinoids Potentiate Synaptic Transmission through Stimulation of Astrocytes , 2010, Neuron.

[137]  T. Uyama,et al.  N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA). , 2010, Progress in lipid research.

[138]  R. Faull,et al.  Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice , 2010, Neuroscience.

[139]  H. Bradshaw,et al.  Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass , 2010, Proceedings of the National Academy of Sciences.

[140]  B. Cravatt,et al.  Characterization of mice lacking candidate N-acyl ethanolamine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivo. , 2010, Molecular bioSystems.

[141]  H. Hansen.  Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain , 2010, Experimental Neurology.

[142]  N. Stella.  Cannabinoid and cannabinoid‐like receptors in microglia, astrocytes, and astrocytomas , 2010, Glia.

[143]  G. Muccioli.  Endocannabinoid biosynthesis and inactivation, from simple to complex. , 2010, Drug discovery today.

[144]  C. Lluis,et al.  Adenosine–cannabinoid receptor interactions. Implications for striatal function , 2010, British journal of pharmacology.

[145]  K. Mackie,et al.  CB2: a cannabinoid receptor with an identity crisis , 2010, British journal of pharmacology.

[146]  S. Petrosino,et al.  N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. , 2010, Biochimie.

[147]  Bret N. Smith,et al.  Effects of TRPV1 activation on synaptic excitation in the dentate gyrus of a mouse model of temporal lobe epilepsy , 2010, Experimental Neurology.

[148]  R. Postuma,et al.  Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations , 2010, Movement disorders : official journal of the Movement Disorder Society.

[149]  G. Pizzolato,et al.  Possible Anandamide and Palmitoylethanolamide involvement in human stroke , 2010, Lipids in Health and Disease.

[150]  V. D. M. A. L. D. Petrocellis.  Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs. , 2010 .

[151]  R. Pertwee.  Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. , 2010, Current medicinal chemistry.

[152]  V. Marzo,et al.  Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. , 2010, Pharmacological research.

[153]  J. Fernández-Ruiz,et al.  The endocannabinoid system as a target for the treatment of neuronal damage , 2010, Expert opinion on therapeutic targets.

[154]  Julie A. Przybyla,et al.  Ligand-Induced Regulation and Localization of Cannabinoid CB1 and Dopamine D2L Receptor Heterodimers , 2010, Journal of Pharmacology and Experimental Therapeutics.

[155]  Masahiko Watanabe,et al.  The Endocannabinoid 2-Arachidonoylglycerol Produced by Diacylglycerol Lipase α Mediates Retrograde Suppression of Synaptic Transmission , 2010, Neuron.

[156]  M. Pangalos,et al.  Loss of Retrograde Endocannabinoid Signaling and Reduced Adult Neurogenesis in Diacylglycerol Lipase Knock-out Mice , 2010, The Journal of Neuroscience.

[157]  T. Bisogno,et al.  Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase. , 2010, Bioorganic & medicinal chemistry letters.

[158]  L. Hunyady,et al.  Signal transduction of the CB1 cannabinoid receptor. , 2010, Journal of molecular endocrinology.

[159]  J. Ferrer,et al.  Crystal Structure of the Human Monoacylglycerol Lipase, a Key Actor in Endocannabinoid Signaling , 2010, Chembiochem : a European journal of chemical biology.

[160]  S. Cuzzocrea,et al.  Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation , 2009, Proceedings of the National Academy of Sciences.

[161]  D. Deutsch,et al.  Lipid Droplets Are Novel Sites of N-Acylethanolamine Inactivation by Fatty Acid Amide Hydrolase-2* , 2009, The Journal of Biological Chemistry.

[162]  I. Mitchell,et al.  A pilot study using nabilone for symptomatic treatment in Huntington's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[163]  T. Bisogno,et al.  Protective role of palmitoylethanolamide in contact allergic dermatitis , 2009, Allergy.

[164]  J. Fernández-Ruiz,et al.  Cannabinoids, multiple sclerosis and neuroprotection , 2009, Expert review of clinical pharmacology.

[165]  Í. Azcoitia,et al.  Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. , 2009, Brain : a journal of neurology.

[166]  V. Marzo,et al.  Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: Possible involvement of the endocannabinoid and endovanilloid systems , 2009, Neurobiology of Disease.

[167]  R. Faull,et al.  Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease , 2009, Neuroscience.

[168]  K. Mackie,et al.  The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo , 2009, Proceedings of the National Academy of Sciences.

[169]  G. Godlewski,et al.  Receptors for acylethanolamides-GPR55 and GPR119. , 2009, Prostaglandins & other lipid mediators.

[170]  E. Brouillet,et al.  Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease , 2009, Glia.

[171]  V. Marzo,et al.  The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. , 2009, Pharmacological research.

[172]  E. Ağar,,et al.  The effects of intracerebroventricular AM‐251, a CB1‐receptor antagonist, and ACEA, a CB1‐receptor agonist, on penicillin‐induced epileptiform activity in rats , 2009, Epilepsia.

[173]  M. Glass,et al.  Cannabinoid (CB1), GABAA and GABAB receptor subunit changes in the globus pallidus in Huntington's disease , 2009, Journal of Chemical Neuroanatomy.

[174]  W. Koek,et al.  WIN55,212‐2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mouse model of Parkinson’s disease , 2009, The European journal of neuroscience.

[175]  M. García,et al.  Enhancement of the hypotensive effects of intrathecally injected endocannabinoids by the entourage compound palmitoylethanolamide. , 2009, European journal of pharmacology.

[176]  K. Verhoeckx,et al.  Development and validation of a quantitative method for the determination of 12 endocannabinoids and related compounds in human plasma using liquid chromatography-tandem mass spectrometry. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[177]  R. Stevens,et al.  Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. , 2009, Chemistry & biology.

[178]  P. Schnable,et al.  The roles of aldehyde dehydrogenases (ALDHs) in the PDH bypass of Arabidopsis , 2009, BMC Biochemistry.

[179]  P. Robledo,et al.  Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons , 2009, Neuropharmacology.

[180]  R. Harris,et al.  Deletion of vanilloid receptor (TRPV1) in mice alters behavioral effects of ethanol , 2009, Neuropharmacology.

[181]  A. Irving,et al.  The GPR55 ligand L‐α‐lysophosphatidylinositol promotes RhoA‐dependent Ca2+ signaling and NFAT activation , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[182]  K. Fisher,et al.  Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. , 2008, Bioorganic & Medicinal Chemistry Letters.

[183]  Benjamin F. Cravatt,et al.  Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects , 2008, Nature chemical biology.

[184]  G. Muccioli,et al.  CAY10499, a Novel Monoglyceride Lipase Inhibitor Evidenced by an Expeditious MGL Assay , 2008, Chembiochem : a European journal of chemical biology.

[185]  D. Barrett,et al.  ‘Entourage’ effects of N‐palmitoylethanolamide and N‐oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors , 2008, British journal of pharmacology.

[186]  B. Costa,et al.  The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARγ receptors and neurotrophic factors , 2008, PAIN.

[187]  G. Uhl,et al.  Functional Expression of Brain Neuronal CB2 Cannabinoid Receptors Are Involved in the Effects of Drugs of Abuse and in Depression , 2008, Annals of the New York Academy of Sciences.

[188]  A. Spagnolo,et al.  Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide , 2008, The European journal of neuroscience.

[189]  David Baker,et al.  The endocannabinoid system and multiple sclerosis. , 2008, Current pharmaceutical design.

[190]  J. Fernández-Ruiz,et al.  The endocannabinoid system in Huntington's disease. , 2008, Current pharmaceutical design.

[191]  Ekaterina A. Placzek,et al.  RNA Interference-Mediated Knockdown of Dynamin 2 Reduces Endocannabinoid Uptake into Neuronal dCAD Cells , 2008, Molecular Pharmacology.

[192]  V. Vellani,et al.  Plant-Derived Cannabinoids Modulate the Activity of Transient Receptor Potential Channels of Ankyrin Type-1 and Melastatin Type-8 , 2008, Journal of Pharmacology and Experimental Therapeutics.

[193]  V. Marzo,et al.  Targeting the endocannabinoid system: to enhance or reduce? , 2008, Nature Reviews Drug Discovery.

[194]  H. Bradshaw,et al.  Prostaglandin E2 glycerol ester, an endogenous COX‐2 metabolite of 2‐arachidonoylglycerol, induces hyperalgesia and modulates NFκB activity , 2008, British journal of pharmacology.

[195]  K. Andreasson,et al.  COX-2 oxidative metabolism of endocannabinoids augments hippocampal synaptic plasticity , 2008, Molecular and Cellular Neuroscience.

[196]  L. Marnett,et al.  Non-redundant Functions of Cyclooxygenases: Oxygenation of Endocannabinoids* , 2008, Journal of Biological Chemistry.

[197]  Masahiko Watanabe,et al.  Downregulation of the CB1 Cannabinoid Receptor and Related Molecular Elements of the Endocannabinoid System in Epileptic Human Hippocampus , 2008, The Journal of Neuroscience.

[198]  C. Reynet,et al.  GPR119, a novel G protein‐coupled receptor target for the treatment of type 2 diabetes and obesity , 2008, British journal of pharmacology.

[199]  George R. Uhl,et al.  Brain Neuronal CB2 Cannabinoid Receptors in Drug Abuse and Depression: From Mice to Human Subjects , 2008, PloS one.

[200]  T. Bisogno,et al.  Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease , 2008, Neurochemistry International.

[201]  N. Stella,et al.  Microglia produce and hydrolyze palmitoylethanolamide , 2008, Neuropharmacology.

[202]  B. Cravatt,et al.  A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2‐Arachidonoylglycerol , 2007, Chemistry & biology.

[203]  Jennifer A. Geaga,et al.  URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. , 2007, Chemistry & biology.

[204]  R. Pertwee.  GPR55: a new member of the cannabinoid receptor clan? , 2007, British journal of pharmacology.

[205]  A. Bilbao,et al.  Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain , 2007, PAIN®.

[206]  M. Pistis,et al.  Endocannabinoid Signaling in Midbrain Dopamine Neurons: More than Physiology? , 2007, Current neuropharmacology.

[207]  S. Hjorth,et al.  The orphan receptor GPR55 is a novel cannabinoid receptor , 2007, British journal of pharmacology.

[208]  A. Yamashita,et al.  Identification of GPR55 as a lysophosphatidylinositol receptor. , 2007, Biochemical and biophysical research communications.

[209]  T. Cassano,et al.  Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: Role of CB1 and TRPV1 receptors , 2007, Experimental Neurology.

[210]  N. Ueda,et al.  Proteolytic activation and glycosylation of N-acylethanolamine-hydrolyzing acid amidase, a lysosomal enzyme involved in the endocannabinoid metabolism. , 2007, Biochimica et biophysica acta.

[211]  F. Drago,et al.  Endocannabinoids and neurodegenerative diseases. , 2007, Pharmacological research.

[212]  R. Capasso,et al.  Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon , 2007, Journal of Molecular Medicine.

[213]  B. Bahr,et al.  Endocannabinoid Enhancement Protects against Kainic Acid-Induced Seizures and Associated Brain Damage , 2007, Journal of Pharmacology and Experimental Therapeutics.

[214]  N. Sang,et al.  COX‐2 oxidative metabolite of endocannabinoid 2‐AG enhances excitatory glutamatergic synaptic transmission and induces neurotoxicity , 2007, Journal of neurochemistry.

[215]  A. Finazzi-Agro’,et al.  Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes , 2007, Neurobiology of Disease.

[216]  A. Carracedo,et al.  Cannabinoids and Gliomas , 2007, Molecular Neurobiology.

[217]  S. Werner,et al.  Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System , 2007, Science.

[218]  M. Ueno,et al.  Predominant expression of lysosomal N-acylethanolamine-hydrolyzing acid amidase in macrophages revealed by immunochemical studies. , 2007, Biochimica et biophysica acta.

[219]  C. Ledent,et al.  Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells , 2007, Nature Medicine.

[220]  K. Valenzano,et al.  The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. , 2007, Current medicinal chemistry.

[221]  C. Gianfrani,et al.  Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats , 2007, Journal of Molecular Medicine.

[222]  L. Petrocellis,et al.  Analgesic actions of N‐arachidonoyl‐serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors , 2007, British journal of pharmacology.

[223]  V. Marzo,et al.  Endocannabinoids and the control of energy balance , 2007, Trends in Endocrinology & Metabolism.

[224]  J. Klosterkötter,et al.  Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry. , 2007, Analytical biochemistry.

[225]  T. Bisogno,et al.  Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats , 2007, Neuropharmacology.

[226]  B. Nilius,et al.  Regulation of TRP channels: a voltage-lipid connection. , 2007, Biochemical Society transactions.

[227]  Ivan Soltesz,et al.  Prevention of Plasticity of Endocannabinoid Signaling Inhibits Persistent Limbic Hyperexcitability Caused by Developmental Seizures , 2007, The Journal of Neuroscience.

[228]  S. Sombati,et al.  Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy , 2007, Neuroscience Letters.

[229]  L. Petrocellis,et al.  Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain , 2006, Neuroscience.

[230]  I. Galve-Roperh,et al.  R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor. , 2006, Biochemical pharmacology.

[231]  T. Mikkelsen,et al.  A Second Fatty Acid Amide Hydrolase with Variable Distribution among Placental Mammals* , 2006, Journal of Biological Chemistry.

[232]  I. Matias,et al.  Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. , 2006, Prostaglandins, leukotrienes, and essential fatty acids.

[233]  J. Luszczki,et al.  Arachidonyl-2'-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model. , 2006, European journal of pharmacology.

[234]  A. Curtis,et al.  Nabilone could treat chorea and irritability in Huntington's disease. , 2006, The Journal of neuropsychiatry and clinical neurosciences.

[235]  H. Bradshaw,et al.  Targeted lipidomics: Discovery of new fatty acyl amides , 2006, The AAPS Journal.

[236]  Atsushi Inoue,et al.  Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. , 2006, Biochemical and biophysical research communications.

[237]  Beat Lutz,et al.  The Endocannabinoid System Controls Key Epileptogenic Circuits in the Hippocampus , 2006, Neuron.

[238]  A. Saghatelian,et al.  A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. , 2006, Biochemistry.

[239]  M. Tominaga,et al.  Increased sensitivity of desensitized TRPV1 by PMA occurs through PKCε-mediated phosphorylation at S800 , 2006, Pain.

[240]  R. E. Blair,et al.  Activation of the Cannabinoid Type-1 Receptor Mediates the Anticonvulsant Properties of Cannabinoids in the Hippocampal Neuronal Culture Models of Acquired Epilepsy and Status Epilepticus , 2006, Journal of Pharmacology and Experimental Therapeutics.

[241]  O. Prospero-Garcia,et al.  Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat. , 2006, Life sciences.

[242]  V. Marzo,et al.  Endocannabinoids and β-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels , 2006, Cellular and Molecular Life Sciences CMLS.

[243]  N. Sang,et al.  PGE2 glycerol ester, a COX‐2 oxidative metabolite of 2‐arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons , 2006, The Journal of physiology.

[244]  C. Brosnan,et al.  Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[245]  R. Pertwee.  The pharmacology of cannabinoid receptors and their ligands: an overview , 2006, International Journal of Obesity.

[246]  T. Bisogno,et al.  Elevation of Endocannabinoid Levels in the Ventrolateral Periaqueductal Grey through Inhibition of Fatty Acid Amide Hydrolase Affects Descending Nociceptive Pathways via Both Cannabinoid Receptor Type 1 and Transient Receptor Potential Vanilloid Type-1 Receptors , 2006, Journal of Pharmacology and Experimental Therapeutics.

[247]  C. Reynet,et al.  Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. , 2006, Cell metabolism.

[248]  Angelo A. Izzo,et al.  The marijuana component cannabidiol inhibits β-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue in PC12 cells , 2006, Journal of Molecular Medicine.

[249]  M. García-Arencibia,et al.  Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease , 2006, Brain Research.

[250]  Y. Maor,et al.  N-arachidonoyl l-serine, an endocannabinoid-like brain constituent with vasodilatory properties , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[251]  A. Hohmann,et al.  Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: Sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla , 2005, Neuropharmacology.

[252]  J. Calixto,et al.  The Effects of Diacerhein on Mechanical Allodynia in Inflammatory and Neuropathic Models of Nociception in Mice , 2005, Anesthesia and analgesia.

[253]  B. Birnir,et al.  Endogenous Unsaturated C18 N-Acylethanolamines Are Vanilloid Receptor (TRPV1) Agonists* , 2005, Journal of Biological Chemistry.

[254]  V. Vellani,et al.  Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels , 2005, The EMBO journal.

[255]  B. Bahr,et al.  Dual Modulation of Endocannabinoid Transport and Fatty Acid Amide Hydrolase Protects against Excitotoxicity , 2005, The Journal of Neuroscience.

[256]  L. Petrocellis,et al.  Lipids as regulators of the activity of transient receptor potential type V1 (TRPV1) channels. , 2005 .

[257]  L. Marnett,et al.  Simultaneous analysis of prostaglandin glyceryl esters and prostaglandins by electrospray tandem mass spectrometry. , 2005, Analytical biochemistry.

[258]  M. Valenti,et al.  Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. , 2005, Biochemical pharmacology.

[259]  Masanobu Kano,et al.  Synaptically Driven Endocannabinoid Release Requires Ca2+-Assisted Metabotropic Glutamate Receptor Subtype 1 to Phospholipase C β4 Signaling Cascade in the Cerebellum , 2005, The Journal of Neuroscience.

[260]  J. Brotchie,et al.  A role for endocannabinoids in the generation of parkinsonism and levodopa‐induced dyskinesia in MPTP‐lesioned non‐human primate models of Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[261]  T. Luger,et al.  Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. , 2005, Journal of dermatological science.

[262]  A. Ferrer-Montiel,et al.  Functional aspects and mechanisms of TRPV1 involvement in neurogenic inflammation that leads to thermal hyperalgesia , 2005, Pflügers Archiv.

[263]  I. Matias,et al.  Finding of endocannabinoids in human eye tissues: implications for glaucoma. , 2005, Biochemical and biophysical research communications.

[264]  N. Ueda,et al.  Molecular Characterization of N-Acylethanolamine-hydrolyzing Acid Amidase, a Novel Member of the Choloylglycine Hydrolase Family with Structural and Functional Similarity to Acid Ceramidase* , 2005, Journal of Biological Chemistry.

[265]  M. L. de Ceballos,et al.  Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation , 2005, The Journal of Neuroscience.

[266]  Hee-Sup Shin,et al.  Phospholipase Cβ Serves as a Coincidence Detector through Its Ca2+ Dependency for Triggering Retrograde Endocannabinoid Signal , 2005, Neuron.

[267]  D. Piomelli,et al.  The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide , 2005, Molecular Pharmacology.

[268]  B. Lutz.  On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. , 2004, Biochemical pharmacology.

[269]  A. Saghatelian,et al.  Reversible Inhibitors of Fatty Acid Amide Hydrolase That Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity , 2004, Journal of Pharmacology and Experimental Therapeutics.

[270]  A. Saghatelian,et al.  Assignment of endogenous substrates to enzymes by global metabolite profiling. , 2004, Biochemistry.

[271]  M. E. Corcoran,et al.  Selective Antiepileptic Effects of N‐Palmitoylethanolamide, a Putative Endocannabinoid , 2004, Epilepsia.

[272]  Giovanni Piersanti,et al.  Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. , 2004, Journal of medicinal chemistry.

[273]  V. Di Marzo,et al.  Actions of two naturally occurring saturated N‐acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels , 2004, British journal of pharmacology.

[274]  A. Hajrasouliha,et al.  The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice , 2004, Neuropharmacology.

[275]  A. Izzo,et al.  Cannabinoids and intestinal motility: welcome to CB2 receptors , 2004, British journal of pharmacology.

[276]  K. Jin,et al.  Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. , 2004, Molecular pharmacology.

[277]  E. Fernández-Espejo,et al.  Effects on turning of microinjections into basal ganglia of D1 and D2 dopamine receptors agonists and the cannabinoid CB1 antagonist SR141716A in a rat Parkinson's model , 2004, Neurobiology of Disease.

[278]  L. Petrocellis,et al.  Prostaglandin Ethanolamides (Prostamides): In Vitro Pharmacology and Metabolism , 2004, Journal of Pharmacology and Experimental Therapeutics.

[279]  Y. Agid,et al.  Neurokinin B, Neurotensin, and Cannabinoid Receptor Antagonists and Parkinson Disease , 2004, Clinical neuropharmacology.

[280]  A. Szallasi,et al.  Biochemical pharmacology of the vanilloid receptor TRPV1 , 2004 .

[281]  N. Ueda,et al.  N-cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase. , 2004, The Biochemical journal.

[282]  B. Cravatt,et al.  Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry Published, JLR Papers in Press, January 16, 2004. DOI 10.1194/jlr.M300475-JLR200 , 2004, Journal of Lipid Research.

[283]  P. Soubrié,et al.  CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity , 2004, International Journal of Obesity.

[284]  N. Ueda,et al.  Molecular Characterization of a Phospholipase D Generating Anandamide and Its Congeners* , 2004, Journal of Biological Chemistry.

[285]  J. Morrow,et al.  The glyceryl ester of prostaglandin E2 mobilizes calcium and activates signal transduction in RAW264.7 cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[286]  Alberto Rábano,et al.  Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains , 2003, The Journal of Neuroscience.

[287]  Gareth Williams,et al.  Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain , 2003, The Journal of cell biology.

[288]  D. Mash,et al.  Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain , 2003, Journal of Neural Transmission.

[289]  M. Eder,et al.  CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity , 2003, Science.

[290]  A. Thompson,et al.  Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. , 2003, Brain : a journal of neurology.

[291]  B. Martin,et al.  The Endogenous Cannabinoid System Regulates Seizure Frequency and Duration in a Model of Temporal Lobe Epilepsy , 2003, Journal of Pharmacology and Experimental Therapeutics.

[292]  M. Guzmán,et al.  Cannabinoids: potential anticancer agents , 2003, Nature Reviews Cancer.

[293]  F. Drago,et al.  Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. , 2003, European journal of pharmacology.

[294]  S. Gaetani,et al.  Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α , 2003, Nature.

[295]  N. Ueda,et al.  Esters, retroesters, and a retroamide of palmitic acid: pool for the first selective inhibitors of N-palmitoylethanolamine-selective acid amidase. , 2003, Journal of medicinal chemistry.

[296]  A. M. Sánchez,et al.  Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. , 2003, Cellular signalling.

[297]  D. Greenberg,et al.  Palmitoylethanolamide Increases after Focal Cerebral Ischemia and Potentiates Microglial Cell Motility , 2003, The Journal of Neuroscience.

[298]  T. Freund,et al.  Long-Term Plasticity of Endocannabinoid Signaling Induced by Developmental Febrile Seizures , 2003, Neuron.

[299]  B. Cravatt,et al.  Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. , 2003, Current opinion in chemical biology.

[300]  E. Brouillet,et al.  Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate , 2003, Neuroreport.

[301]  P. Calabresi,et al.  Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism , 2003, Journal of neurochemistry.

[302]  L. Petrocellis,et al.  N-Oleoyldopamine, a Novel Endogenous Capsaicin-like Lipid That Produces Hyperalgesia* , 2003, The Journal of Biological Chemistry.

[303]  J. Borrell,et al.  Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis , 2003, The Journal of Neuroscience.

[304]  T. Vanderah,et al.  CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? , 2003, Current opinion in pharmacology.

[305]  N. Milton.  Anandamide and noladin ether prevent neurotoxicity of the human amyloid-β peptide , 2002, Neuroscience Letters.

[306]  S. Conti,et al.  Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo‐oxygenase systems , 2002, British journal of pharmacology.

[307]  P. Calabresi,et al.  Experimental Parkinsonism Alters Endocannabinoid Degradation: Implications for Striatal Glutamatergic Transmission , 2002, The Journal of Neuroscience.

[308]  S. Schwab,et al.  Release of Fatty Acid Amides in a Patient With Hemispheric Stroke: A Microdialysis Study , 2002, Stroke.

[309]  Tomomi Shirai,et al.  Pharmacological studies of diacerein in animal models of inflammation, arthritis and bone resorption. , 2002, European journal of pharmacology.

[310]  Rajnish A. Gupta,et al.  15-Lipoxygenase Metabolism of 2-Arachidonylglycerol , 2002, The Journal of Biological Chemistry.

[311]  T. Möller,et al.  Astrocytes in Culture Produce Anandamide and Other Acylethanolamides* , 2002, The Journal of Biological Chemistry.

[312]  P. Jenner,et al.  Increased cannabinoid CB1 receptor binding and activation of GTP‐binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP‐treated marmosets , 2001, The European journal of neuroscience.

[313]  J. Walker,et al.  Identification of a New Class of Molecules, the Arachidonyl Amino Acids, and Characterization of One Member That Inhibits Pain* , 2001, The Journal of Biological Chemistry.

[314]  S. Gaetani,et al.  An anorexic lipid mediator regulated by feeding , 2001, Nature.

[315]  R. Capasso,et al.  Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice , 2001, British journal of pharmacology.

[316]  V. Di Marzo,et al.  Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors , 2001, FEBS letters.

[317]  J. Morrow,et al.  Metabolism of Prostaglandin Glycerol Esters and Prostaglandin Ethanolamides in Vitro and in Vivo * , 2001, The Journal of Biological Chemistry.

[318]  N. Ueda,et al.  Purification and Characterization of an Acid Amidase Selective for N-Palmitoylethanolamine, a Putative Endogenous Anti-inflammatory Substance* , 2001, The Journal of Biological Chemistry.

[319]  Daniele Piomelli,et al.  Receptor-dependent formation of endogenous cannabinoids in cortical neurons. , 2001, European journal of pharmacology.

[320]  L. Petrocellis,et al.  Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. , 2001, The Biochemical journal.

[321]  A. Howlett,et al.  Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates , 2001, Psychopharmacology.

[322]  M. Elphick,et al.  The neurobiology and evolution of cannabinoid signalling. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[323]  Heping Cheng,et al.  Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses , 2001, Nature.

[324]  S. Vandevoorde,et al.  Anticonvulsant Activity of N‐Palmitoylethanolamide, a Putative Endocannabinoid, in Mice , 2001, Epilepsia.

[325]  T. Bisogno,et al.  Endocannabinoids control spasticity in a multiple sclerosis model , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[326]  B. Picconi,et al.  Role of tonically-active neurons in the control of striatal function: Cellular mechanisms and behavioral correlates , 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[327]  A. Howlett,et al.  Cellular signal transduction by anandamide and 2-arachidonoylglycerol. , 2000, Chemistry and physics of lipids.

[328]  H. Hansen,et al.  N-Acylethanolamines and precursor phospholipids - relation to cell injury. , 2000, Chemistry and physics of lipids.

[329]  J. Brotchie,et al.  Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[330]  M. Dragunow,et al.  The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease , 2000, Neuroscience.

[331]  G. Velasco,et al.  The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. , 2000, The Biochemical journal.

[332]  Z. Dong,et al.  Stress-induced generation of N-acylethanolamines in mouse epidermal JB6 P+ cells. , 2000, The Biochemical journal.

[333]  R. Hampson,et al.  Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture. , 1999, The Journal of pharmacology and experimental therapeutics.

[334]  H. Emrich,et al.  Nabilone increases choreatic movements in Huntington's disease , 1999, Movement disorders : official journal of the Movement Disorder Society.

[335]  M. Lagarde,et al.  Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina. , 1999, Archives of biochemistry and biophysics.

[336]  L. Dekker,et al.  Specific Involvement of PKC-ε in Sensitization of the Neuronal Response to Painful Heat , 1999, Neuron.

[337]  A. Howlett.  The CB1Cannabinoid Receptor in the Brain , 1998, Neurobiology of Disease.

[338]  L. Petrocellis,et al.  Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. , 1998, Biochemical and biophysical research communications.

[339]  L. Petrocellis,et al.  An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. , 1998, European journal of pharmacology.

[340]  D. Piomelli,et al.  Control of pain initiation by endogenous cannabinoids , 1998, Nature.

[341]  L. Petrocellis,et al.  The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. , 1998, The Biochemical journal.

[342]  D. Piomelli,et al.  Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma , 1998, FEBS letters.

[343]  S. Yamamoto,et al.  Anandamide amidohydrolase reacting with 2‐arachidonoylglycerol, another cannabinoid receptor ligand , 1998, FEBS letters.

[344]  D. Julius,et al.  The capsaicin receptor: a heat-activated ion channel in the pain pathway , 1997, Nature.

[345]  B. Cravatt,et al.  Molecular characterization of human and mouse fatty acid amide hydrolases. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[346]  J. H. Li,et al.  Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[347]  Stephen P. Mayfield,et al.  Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.

[348]  A. Buriani,et al.  The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[349]  S. Galiègue,et al.  Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. , 1995, European journal of biochemistry.

[350]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[351]  A. Buriani,et al.  Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[352]  J. Schwartz,et al.  Formation and inactivation of endogenous cannabinoid anandamide in central neurons , 1994, Nature.

[353]  J. Vanderhaeghen,et al.  Dopaminergic Regulation of Cannabinoid Receptor mRNA Levels in the Rat Caudate‐Plitamen: An In Situ Hybridization Study , 1993, Journal of neurochemistry.

[354]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[355]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[356]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[357]  M. Herkenham,et al.  Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[358]  C. Raine,et al.  Experimental autoimmune encephalomyelitis: isolation and characterization of inflammatory cells from the central nervous system , 1989, Journal of Neuroimmunology.

[359]  T. Iwata,et al.  Immunological characterization of sn-1,2-diacylglycerol and sn-2-monoacylglycerol kinase from pig brain. , 1986, The Journal of biological chemistry.

[360]  R. Coleman,et al.  Monoacylglycerol acyltransferase. Evidence that the activities from rat intestine and suckling liver are tissue-specific isoenzymes. , 1986, The Journal of biological chemistry.

[361]  D. Epps,et al.  N-Acylethanolamine accumulation in infarcted myocardium. , 1979, Biochemical and biophysical research communications.

[362]  K. Melmon,et al.  FATTY ACID AMIDES OF ETHANOLAMINE IN MAMMALIAN TISSUES. , 1965, The Journal of biological chemistry.

[363]  R. Mechoulam,et al.  Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish , 1964 .

[364]  O. Ganley,et al.  Anti-inflammatory activity on compounds obtained from egg yolk, peanut oil, and soybean lecithin. , 1958, The Journal of laboratory and clinical medicine.

[365]  F. Kuehl,et al.  THE IDENTIFICATION OF N-(2-HYDROXYETHYL)-PALMITAMIDE AS A NATURALLY OCCURRING ANTI-INFLAMMATORY AGENT , 1957 .

[366]  A. Coburn,et al.  THE EFFECT OF EGG YOLK IN DIETS ON ANAPHYLACTIC ARTHRITIS (PASSIVE ARTHUS PHENOMENON) IN THE GUINEA PIG , 1954, The Journal of experimental medicine.

[367]  S. Cuzzocrea,et al.  Diacerein is a potent and selective inhibitor of palmitoylethanolamide inactivation with analgesic activity in a rat model of acute inflammatory pain. , 2015, Pharmacological research.

[368]  F. Vernieri,et al.  Elevation of Plasma 2-Arachidonoylglycerol Levels in Alzheimer's Disease Patients as a Potential Protective Mechanism against Neurodegenerative Decline. , 2015, Journal of Alzheimer's disease : JAD.

[369]  J. Gertsch,et al.  Endocannabinoid transport revisited. , 2015, Vitamins and hormones.

[370]  William R Arnold,et al.  Endocannabinoid metabolism by cytochrome P450 monooxygenases. , 2015, Prostaglandins & other lipid mediators.

[371]  Dominic Friston,et al.  Pharmacology of the capsaicin receptor, transient receptor potential vanilloid type-1 ion channel. , 2014, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[372]  R. Tuma,et al.  Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS. , 2014, Cellular immunology.

[373]  J. G. Edwards.  TRPV1 in the central nervous system: synaptic plasticity, function, and pharmacological implications. , 2014, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[374]  A. Cavalli,et al.  Synthesis and Structure − Activity Relationship (SAR) of 2 ‑ Methyl-4-oxo-3-oxetanylcarbamic Acid Esters, a Class of Potent N ‑ Acylethanolamine Acid Amidase (NAAA) Inhibitors , 2013 .

[375]  I. Ferrer,et al.  CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice. , 2013, Journal of Alzheimer's disease : JAD.

[376]  W. Guo,et al.  Increased Expression of TRPV1 in the Cortex and Hippocampus from Patients with Mesial Temporal Lobe Epilepsy , 2012, Journal of Molecular Neuroscience.

[377]  I. Ferrer,et al.  CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AβPP/PS1 mice. , 2012, Journal of Alzheimer's disease : JAD.

[378]  P. Szulczyk,et al.  EFFECT OF CYCLIC ADENOSINE MONOPHOSPHATE ON THE G PROTEIN-DEPENDENT INWARD RECTIFIER K+-LIKE CHANNEL CURRENT IN MEDIAL PREFRONTAL CORTEX PYRAMIDAL NEURONS , 2012 .

[379]  L. Chahl.  TRP channels and psychiatric disorders. , 2011, Advances in experimental medicine and biology.

[380]  S. Petrosino,et al.  FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. , 2010, Current opinion in investigational drugs.

[381]  S. Banni,et al.  Effect of dietary fat on endocannabinoids and related mediators: consequences on energy homeostasis, inflammation and mood. , 2010, Molecular nutrition & food research.

[382]  V. Marzo.  Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight , 2010, Nature Neuroscience.

[383]  T. Bisogno,et al.  Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. , 2009, Biochimica et biophysica acta.

[384]  V. Di Marzo,et al.  TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. , 2008, Current pharmaceutical design.

[385]  V. Marzo,et al.  Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. , 2007, Veterinary journal.

[386]  V. Marzo,et al.  Endocannabinoid synthesis and degradation, and their regulation in the framework of energy balance. , 2006, Journal of endocrinological investigation.

[387]  A. Molleman,et al.  Cannabinoid signalling (review) , 2006 .

[388]  R. Levi‐montalcini,et al.  A proposed autacoid mechanism controlling mastocyte behaviour , 2005, Agents and Actions.

[389]  I. Galve-Roperh,et al.  Control of the cell survival/death decision by cannabinoids , 2001, Journal of Molecular Medicine.

[390]  J. Manzanares,et al.  Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. , 2000, Life sciences.

[391]  R. Pertwee.  Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.

[392]  T. Sugiura,et al.  2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. , 1995, Biochemical and biophysical research communications.